Dr. Priyom Bose

Feature Writer

B.Sc. Botany, M.Sc. Plant Biology and Biotechnology, Ph.D. Plant Biology and Biotechnology

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Articles from Priyom

Evaluation of Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities

The severity of COVID-19 among the residents of long-term care facilities (LTCFs) has been reported to be disproportionately high. Specifically, individuals residing in skilled nursing facilities (SNFs) are found to be the most severely affected, both in terms of morbidity and mortality, and are, thereby, listed for early COVID-19 vaccination. In comparison to the general population, SNF residents are more vulnerable, with a weak immune system.

17 Mar 2021

An increase in the risk of clinical sequelae after SARS-CoV-2 infection

A new piece of research, published on the medRxiv preprint server, focused on the role of factors such as gender, age, hospitalization, etc., in understanding the risks of clinical sequelae in the post-acute phase of COVID-19, in adults aged between 18 and 65 years.

15 Mar 2021

Study suggests COVID-19 vaccine acceptance on the rise in UK

A team of researchers in the UK recently conducted a two-wave survey on the hesitancy of individuals to receive COVID-19 vaccination.

15 Mar 2021

SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment, study finds

Researchers have found that SARS-CoV-2 is extremely sensitive to type I IFN pre-treatment. Therefore, strategies such as focusing on limiting the production of IFN, rather than its function, could restrict the mechanism of SARS-CoV-2 that increases its viral load with delayed or absent symptoms.

12 Mar 2021

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

A new study deals with the evaluation of adaptive immune response to COVID-19 vaccination in candidates who have recovered from SARS-CoV-2 infection.

11 Mar 2021

2% of individuals carry 90% of SARS-CoV-2 virions: Study of 72,500 tests

In a new study published on the medRxiv* preprint server, researchers analyzed viral loads from pre-symptomatic and asymptomatic individuals in an extensive university surveillance program.

9 Mar 2021

How do viruses evolve in bats?

Bats have played a crucial epidemiological role in the evolution of many viruses and house many coronaviruses. Until 2002, coronaviruses had been known to cause mild respiratory ailments in human beings. However, this notion changed in the same year when a bat-borne virus caused the severe acute respiratory syndrome (SARS) pandemic.

8 Mar 2021

How can physicians distinguish between COVID-19 persistence and SARS-CoV-2 reinfection?

One of the most challenging tasks of physicians has been differentiating between persistent COVID-19 and SARS-CoV-2 reinfection. Recently, a team of researchers analyzed SARS-CoV-2 sequences from the publicly available reports on reinfection and persistence. They further characterized the markers of reinfecting sequences and studied the mutation rate in newly evolved persistent variants.

8 Mar 2021

Identification of neutralizing IFNL3 autoantibodies in severe COVID-19 cases

Scientists have recently developed a novel alternative molecular display technology called Molecular Indexing of Proteins by Self Assembly (MIPSA). Their research explains how this technology overcomes the critical disadvantages of PLATO and other full-length protein array technologies.

5 Mar 2021

Study reports persistent SARS-CoV-2 with increasing viral variants in pediatric patients

New research, published on medRxiv preprint server, has reported the effect of prolonged SARS-CoV-2 infection in immunocompromised children and young adults.

4 Mar 2021